Abstract
Background: the diagnosis of idiopathic growth hormone deficiency remains a challenge for the clinician. The uncertainties in the cut-off values to describe growth hormone deficiency and reference data for growth hormone secretion in normally growing children, differences in growth hormone assays over the time, problems in reproducibility of growth hormone test results all contribute to this vagueness. However, diagnosing growth hormone deficiency is important to identify children who will benefit most from the GH treatment. GH dependent peptides, insulin-like growth factor I (IGF-I) and insulin-like growth factor-binding protein 3, (IGFBP-3) are good markers of growth hormone status and are useful in diagnosing GH deficiency as well as monitoring efficacy of growth hormone treatment.
Objective: The aim of this study was to evaluate the role of IGF-1level in diagnosed short stature children without clear cause and had one of the following criteria.
Patients and method: cross sectional study comprised all short children seen in our Pediatric Endocrinology Unit in AL-Diwaniya maternity and children hospital from October 2021 to October 2022. IGF1-deficient children were defined as children without GH deficiency and with IGF1 levels below or equal to -2 SDS
Results: Among 37 children with isolated SS, 7 (18.91%) had low IGF-1 levels and normal GH level, consistent with a diagnosis of primary IGFD and 9(24.32%) non -growing, GHD children had normal IGF-1 levels
Conclusion: IGF-1 level has important clinical role in non-GHD, non-growing SS children.
References
1. Inzaghi E, Reiter E, Cianfarani S. The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy. Hormone Research in Paediatrics. 2020 Oct 2;92(2):71-83.
2. Domené S, Domene HM. Genetic mutations in the GH/IGF axis. Pediatric Endocrinology Reviews 2018;16:82-105.
3. Dauber A, Meng Y, Audi L, Vedantam S, Weaver B, Carrascosa A, Albertsson-Wikland K, Ranke MB, Jorge AA, Cara J, Wajnrajch MP. A genome-wide pharmacogenetic study of growth hormone responsiveness. The Journal of Clinical Endocrinology & Metabolism. 2020 Oct;105(10):3203-14.
4. Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J. Dose‐sparing and safety‐enhancing effects of an IGF‐I‐based dosing regimen in short children treated with growth hormone in a 2‐year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clinical endocrinology. 2014 Jul;81(1):71-6.
5. Jimenez AB, Gea IL, Ollero MJ, Lopez-Siguero JP. Growth Hormone deficiency and Idiopathic short stature. Efficacy after growth hormone treatment up to adult height. Authorea Preprints. 2024 Jan 31.
6. Pugliese-Pires PN, Fortin JP, Arthur T, Latronico AC, Mendonca BB, Villares SM, Arnhold IJ, Kopin AS, Jorge AA. Novel inactivating mutations in the GH secretagogue receptor gene in patients with constitutional delay of growth and puberty. European journal of Endocrinology. 2011 Aug;165(2):233-41.
7. Kang MJ. Novel genetic cause of idiopathic short stature. Annals of pediatric endocrinology & metabolism. 2017 Sep 28;22(3):153-7.
8. Andrade NL, Cellin LP, Rezende RC, Vasques GA, Jorge AA. Idiopathic short stature: what to expect from genomic investigations. Endocrines. 2023 Jan 9;4(1):1-7.
9. Polidori N, Castorani V, Mohn A, Chiarelli F. Deciphering short stature in children. Annals of pediatric endocrinology & metabolism. 2020 Jun 30;25(2):69-79.
10. Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J. Dose‐sparing and safety‐enhancing effects of an IGF‐I‐based dosing regimen in short children treated with growth hormone in a 2‐year randomized controlled trial: therapeutic and pharmacoeconomic considerations. Clinical endocrinology. 2014 Jul;81(1):71-6.
11. Kriström B, Lundberg E, Jonsson B, Albertsson-Wikland K, Study Group. IGF-1 and growth response to adult height in a randomized GH treatment trial in short non-GH-deficient children. The Journal of Clinical Endocrinology & Metabolism. 2014 Aug 1;99(8):2917-24.
12. Argente J, Tatton-Brown K, Lehwalder D, Pfäffle R. Genetics of growth disorders—which patients require genetic testing?. Frontiers in Endocrinology. 2019 Sep 6;10:602.
13. Ekström K, Salemyr J, Zachrisson I, Carlsson-Skwirut C, Ortqvist E, Bang P: Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Diabetes Care 2007;30:1357–1363.
14. Ranke MB, Schweizer R, Elmlinger MW, Weber K, Binder G, et al.Significance of basal IGF-I, IGFBP-3 and IGFBP-2 measurements in the diagnostics of short stature inchildren. Horm Res 2000; 54:p. 60–68.
15. Abdullah Bereket. Diagnosis of Growth Hormone Deficiency: the role of Growth Hormone (GH), Insulin- Like Growth Factor (IGF-I) and IGF-Binding Protein (IGFBP-3) . Marmara University Medical School, Pediatric Endocrinology Department,2009;(Suppl 1):p.23–35
16. Edouard,S Gru¨nenwald2, I Genneroe tal.Prevalence of IGF1 deficiency in prepubertal children with isolated short stature. European Journal of Endocrinology (2009) 161;p. 43–50
17. Attie KM, Julius JR, Stoppani C & Rundle AC. National CooperativeGrowth Study substudy VI: the clinical utility of growth-hormonebindingprotein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. Journal of Pediatrics 1997; 131.p.56–60.
18. Clayton PE, Ayoola O & Whatmore AJ. Patient selection for IGF-1therapy. Hormone Research 2006; 65.p. 28–34.
19. Collett-Solberg PF & Misra M. The role of recombinant humaninsulin-like growth factor-I in treating children with short stature. Journal of Clinical Endocrinology and Metabolism 2008; 93 10–18.
20. Rosenfeld RG, Wilson DM, Lee PDK, Hintz RL. Insulin-like growth factors I and II in evaluation ofgrowth retardation. J Pediatr1986; 109:p.428-433.
21. John S. Parks, Eric I. Felner . The endocrine system . Saunders E lsevier . Nelson Textbook of Pediatrics. 19th edition . 2011 ; p.2291-2299
22. P. Cohen, A. D. Rogol, C. L. Deal, et al . Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop . J Clin Endocrinol Metab. November 2008, 93(11):p.4210–4217
23. P. Cohen, A. D. Rogol, C. L. Deal, et al . Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop . J Clin Endocrinol Metab. November 2008, 93(11):p.4210–4217
24. Juul A, Skakkebaek NE. Prediction of the outcome of growth hormone provocative testing in shortchildren by measurement of serum levels of insulin-like growth factor I and insulin-like growth factorbinding protein-3. J Pediatr 1997; 130:p.197-204.